| 摘要 |
<p num="1"><br/><br/>The present invention is directed to a combination of therapeutic compounds <br/>and <br/>treatment methods and kits using the combination. In particular, one of the <br/>combination <br/>affects the NC ca-ATp channel of neural tissue, including neurons, glia and <br/>blood vessels <br/>within the nervous system. Exemplary SUR1 and/or TRPM4 antagonists that <br/>inhibit the <br/>NC ca-ATP channel may be employed in the combination. The combination therapy <br/>also <br/>employs one or more of a non-selective cation channel blocker and/or an <br/>antagonist of <br/>VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy <br/><br/>includes the prevention, diminution, and/or treatment of injured or diseased <br/>neural tissue, <br/>including astrocytes, neurons and capillary endothelial cells, that is due to <br/>ischemia, tissue <br/>trauma, brain swelling and increased tissue pressure, or other forms of brain <br/>or spinal cord <br/>disease or injury, for example. In other embodiments, there are methods and <br/>compositions <br/>directed to antagonists of TRPM4, including at least for therapeutic treatment <br/>of traumatic <br/>brain injury, cerebral ischemia, central nervous system (CNS) damage, <br/>peripheral nervous <br/>system (PNS) damage, cerebral hypoxia, or edema, for example.<br/>
|
